Abstract:Background. Microarray technology enables a standardized, objective assessment of oncological diagnosis and prognosis. However, such studies are typically specific to certain cancer types, and the results have limited use due to inadequate validation in large patient cohorts. Discovery of genes commonly regulated in cancer may have an important implication in understanding the common molecular mechanism of cancer. Methods and Findings. We described an integrated gene-expression analysis of 2,186 samples from 39 studies to identify and validate a cancer type-independent gene signature that can identify cancer patients for a wide variety of human malignancies. The commonness of gene expression in 20 types of common cancer was assessed in 20 training datasets. The discriminative power of a signature defined by these common cancer genes was evaluated in the other 19 independent datasets including novel cancer types. QRT-PCR and tissue microarray were used to validate commonly regulated genes in multiple cancer types. We identified 187 genes dysregulated in nearly all cancerous tissue samples. The 187-gene signature can robustly predict cancer versus normal status for a wide variety of human malignancies with an overall accuracy of 92.6%. We further refined our signature to 28 genes confirmed by QRT-PCR. The refined signature still achieved 80% accuracy of classifying samples from mixed cancer types. This signature performs well in the prediction of novel cancer types that were not represented in training datasets. We also identified three biological pathways including glycolysis, cell cycle checkpoint II and plk3 pathways in which most genes are systematically up-regulated in many types of cancer. Conclusions. The identified signature has captured essential transcriptional features of neoplastic transformation and progression in general. These findings will help to elucidate the common molecular mechanism of cancer, and provide new insights into cancer diagnostics, prognostics and therapy.

Additional File 6 of Proteomic Signatures of 16 Major Types of Human Cancer Reveal Universal and Cancer-Type-specific Proteins for the Identification of Potential Therapeutic Targets

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Additional File 1 of Integration of Single-Cell Regulon Atlas and Multi-Omics Data for Prognostic Stratification and Personalized Treatment Prediction in Human Lung Adenocarcinoma

Additional File 1 of Genetic Alterations and Functional Networks of M6a RNA Methylation Regulators in Pancreatic Cancer Based on Data Mining

Common Human Cancer Genes Discovered by Integrated Gene-Expression Analysis

Additional File 2 of Identification and Validation of a Six-Gene Signature Associated with Glycolysis to Predict the Prognosis of Patients with Cervical Cancer

Additional File 6 of Comparative Profiling of Single-Cell Transcriptome Reveals Heterogeneity of Tumor Microenvironment Between Solid and Acinar Lung Adenocarcinoma

Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers

Table S1 from Proteomic Profiling of Serum Extracellular Vesicles Identifies Diagnostic Signatures and Therapeutic Targets in Breast Cancer

Additional File 8 of Single-cell Landscape of Immunocytes in Patients with Extrahepatic Cholangiocarcinoma

Additional File 1 of Identification of a Tumor Microenvironment-Related Seven-Gene Signature for Predicting Prognosis in Bladder Cancer

Additional File 29 of Proteogenomic Insights into the Biology and Treatment of Pancreatic Ductal Adenocarcinoma

Systematic Characterization of M6a Proteomics Across 12 Cancer Types: a Multi-Omics Integration Study.

Supplementary Table 2 from Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer

Additional File 6 of A Human Lung Tumor Microenvironment Interactome Identifies Clinically Relevant Cell-Type Cross-Talk

Additional File 28 of Proteogenomic Insights into the Biology and Treatment of Pancreatic Ductal Adenocarcinoma

Additional File 5 of A Novel Signature of Two Long Non-Coding RNAs in BRCA Mutant Ovarian Cancer to Predict Prognosis and Efficiency of Chemotherapy